As of Q4'25, APH reported SG&A Expenses of USD 691M and R&D Expenses of USD 0, marking the latest data point in the period from Q1'23 to Q4'25. There has been no recorded spending on R&D throughout this timeframe. The chart reveals a consistent upward trend in SG&A Expenses, rising from USD 346.3M in Q1'23 to USD 691M in Q4'25, nearly doubling over the observed period. This steady increase indicates expanding operational costs, while the absence of R&D Expenses suggests a lack of investment in research and development during these quarters.